Browsing by Author Chmielowski, Bartosz

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)Citation
2014Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trialKefford, Richard (Rick); Boasberg, Peter; Chmielowski, Bartosz; Daud, Adil; Dronca, Roxana; Ebbinghaus, Scot; Elassaiss-Schaap, Jeroen; Gangadhar, Tara C.; Gergich, Kevin; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Iannone, Robert; Joseph, Richard W.; Joshua, Anthony M.; Kang, Peter; Li, Xiaoyun; Mateus, Christine; Patnaik, Amita; Postow, Michael; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Western Clinical School: Westmead Millennium InstituteAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial, The Lancet, vol.384, 9948, 2014,pp 1109-1117
2012Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF InhibitorsKefford, Richard (Rick); Long, Georgina; Pupo, Gulietta; Bacchiocchi, Antonella; Chmielowski, Bartosz; Dahlman, Kimberly; Halaban, Ruth; Kong, Xiangju; Koya, Richard; Lo, Roger; Moriceau, Gatien; Nazarian, Ramin; Ribas, Antoni; Shi, Hubing; Sosman, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Medicine (Westmead)Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors, Cancer Discovery, vol.2, 5, 2012,pp 414-424